Cadila Healthcare
Covid-19 prescription: Pharma players shift their focus over the counter
Covid-19: At Rs 2,800 per dose, Zydus launches cheapest remdesivir brand
Zydus launches cheapest remdesivir at Rs 2,800 per 100 mg vial in India
US-led growth helps Cadila post steady Q1 show even as India biz falters
Cadila Healthcare slips 4.5% from day's high post June quarter results

Nifty view and stock picks by Anand Rathi: Buy Tata Consumer, Sell Escorts
Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy
Here's a Bull Spread strategy for Cadila Healthcare by HDFC Securities
Six Indian drug firms that are doing serious business in coronavirus times
Cadila gains 5% on DGCI nod for clinical trials of Covid-19 vaccine

Cadila's renewed focus on India biz, Covid-19 opportunities lend confidence
Cadila-CSIR's sepsis drug shows promise in fight against Covid-19
Cadila Healthcare's Q4 PBT falls 14% to Rs 522 cr, total income rises 0.66%
MARKET WRAP: Indices extend gains, Sensex up 524 pts as RIL surges over 6%
Market Ahead, June 19: Top factors that could guide markets today
Amidst controversy, Indian companies continue to manufacture HCQ
Cadila to make India's first indigenous antibody test kit: Health Minister
Nifty needs to hold 9,150 for further up move: Nilesh Jain of Anand Rathi
In race to stop Covid-19, Indian drugmakers to conduct clinical trials
Cadila Healthcare at the forefront, looks at biologic drug to treat Covid